A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea

2013174 citationsJournal Articlehybrid Open Access

Authors

Srđan Verstovšek · The University of Texas MD Anderson Cancer Center

Francesco Passamonti · Ospedale di Circolo e Fondazione Macchi

Alessandro Rambaldi · Ospedale Papa Giovanni XXIII

Giovanni Barosi · Policlinico San Matteo Fondazione

Peter J. Rosen · Tower Cancer Research Foundation

Elisa Rumi · Istituti di Ricovero e Cura a Carattere Scientifico

Elisabetta Gattoni

Abstract

Ruxolitinib was generally well tolerated and provided rapid and durable clinical benefits in patients with advanced PV who were refractory or intolerant to hydroxyurea.

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Myeloid Leukemia Research Kruppel-like factors research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 120, Issue 4, pp. 513-520

DOI: 10.1002/cncr.28441

Field-Weighted Citation Impact: 15.41